ATYR
aTYR PHARMA INC
$0.53
+0.05 (+9.94%)
At close · Jul 15
Market Cap
$49.96M
Shares
98,051,212
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.53
Open$0.52
Day$0.50–0.56
52W$0.42–7.29
Avg vol 30d2.2M
Short int14.5M · 14.8% float · 5.1d
Short vol52%
Last earningsMar 13, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.7 · calm
Equity put/call 0.69
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−6%
below
RSI (14)
48
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
+16%
trailing
6-month return
−25%
trailing
YTD return
−32%
this year
Relative strength
−35%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
8 of 112 funds reported for Jun 30 · net +183.1K sh shares · +2 new
Insider flow
Accumulating
Net +$49.6K over 90 days · 0% sells
Short interest
Falling
14.79% of float · ▼ -21.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
112 holders — mid 3-yr range
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−19%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-62.1M
Balance sheet
$6.3M
net debt
Quant / Vol
risk profile
Volatility
137%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
11.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
48
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
8 of 112 funds reported for Jun 30 · net +183.1K sh shares · +2 new
Insider flow
Accumulating
Net +$49.6K over 90 days · 0% sells
Short interest
Falling
14.79% of float · ▼ -21.6% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
112 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $1 · 2%
52-wk high $7
vs 200-day avg -30%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ATYR
this stock
aTYR PHARMA INC
|
$49.96M | -31.8% | -96.6% | — | 14.8% |
|
ONC
BeOne Medicines Ltd.
|
$449.85B | +2.5% | +22179.2% | 915.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +5.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -13.8% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.6% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ATYR | -16.9% | +16.4% | -24.6% | -10.5% | -31.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | -18.2% | +16.5% | -34.8% | -11.6% | -42.5% |